- Home
- NVGS vs SPRY Comparison
NVGS vs SPRY Comparison
Compare NVGS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVGS | SPRY |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 833.1M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NVGS | SPRY |
|---|---|---|
| Price | $19.99 | $8.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $21.50 | ★ $40.00 |
| AVG Volume (30 Days) | 510.5K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $90.76 |
| Revenue Next Year | N/A | $81.70 |
| P/E Ratio | $13.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.62 | $6.66 |
| 52 Week High | $21.36 | $18.63 |
Technical Indicators
Market Signals| Indicator | NVGS | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 45.73 |
| Support Level | $17.38 | $8.05 |
| Resistance Level | $21.36 | $8.70 |
| Average True Range (ATR) | 0.64 | 0.54 |
| MACD | 0.10 | 0.07 |
| Stochastic Oscillator | 89.44 | 66.13 |
Price Performance
Historical ComparisonAbout NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.